Lindsay McKenna

1.0k total citations
25 papers, 265 citations indexed

About

Lindsay McKenna is a scholar working on Infectious Diseases, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Lindsay McKenna has authored 25 papers receiving a total of 265 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 10 papers in Epidemiology and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Lindsay McKenna's work include Tuberculosis Research and Epidemiology (21 papers), Pharmaceutical studies and practices (8 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Lindsay McKenna is often cited by papers focused on Tuberculosis Research and Epidemiology (21 papers), Pharmaceutical studies and practices (8 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Lindsay McKenna collaborates with scholars based in United States, South Africa and United Kingdom. Lindsay McKenna's co-authors include James A. Seddon, Anthony J. Garcia‐Prats, Dzintars Gotham, Mike Frick, Valma J Robertson, Kate Whelan, Lucy Chipchase, Erica Lessem, H. Simon Schaaf and Jennifer Furin and has published in prestigious journals such as PLoS ONE, American Journal of Respiratory and Critical Care Medicine and Clinical Infectious Diseases.

In The Last Decade

Lindsay McKenna

24 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lindsay McKenna United States 10 191 122 83 33 22 25 265
Erica Lessem United States 9 180 0.9× 132 1.1× 53 0.6× 21 0.6× 23 1.0× 15 227
Catherine Hewison France 10 280 1.5× 228 1.9× 95 1.1× 20 0.6× 9 0.4× 13 316
Nicole Salazar‐Austin United States 11 198 1.0× 142 1.2× 92 1.1× 25 0.8× 9 0.4× 31 270
P. Gräf Germany 10 209 1.1× 202 1.7× 221 2.7× 16 0.5× 20 0.9× 24 455
Joseph Drabo Burkina Faso 13 228 1.2× 68 0.6× 24 0.3× 11 0.3× 9 0.4× 25 357
Julia Coit United States 9 248 1.3× 185 1.5× 106 1.3× 12 0.4× 3 0.1× 18 295
Oswaldo Jave Peru 10 228 1.2× 185 1.5× 84 1.0× 8 0.2× 7 0.3× 17 278
Burcu Ceylan Cura Yayla Türkiye 9 165 0.9× 43 0.4× 65 0.8× 15 0.5× 3 0.1× 21 253
Charles M. Crane United States 7 310 1.6× 242 2.0× 166 2.0× 14 0.4× 6 0.3× 8 407
Alexandra B. Souza Brazil 9 169 0.9× 133 1.1× 36 0.4× 11 0.3× 13 0.6× 17 222

Countries citing papers authored by Lindsay McKenna

Since Specialization
Citations

This map shows the geographic impact of Lindsay McKenna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindsay McKenna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindsay McKenna more than expected).

Fields of papers citing papers by Lindsay McKenna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindsay McKenna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindsay McKenna. The network helps show where Lindsay McKenna may publish in the future.

Co-authorship network of co-authors of Lindsay McKenna

This figure shows the co-authorship network connecting the top 25 collaborators of Lindsay McKenna. A scholar is included among the top collaborators of Lindsay McKenna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindsay McKenna. Lindsay McKenna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mangan, Joan M., Mike Frick, Lindsay McKenna, et al.. (2024). Facilitators and barriers to adolescent participation in a TB clinical trial. The International Journal of Tuberculosis and Lung Disease. 28(5). 243–248.
2.
Stillo, Jonathan, et al.. (2023). Addressing the needs of people with extensively drug-resistant TB through pre-approval access to drugs and research. Public Health Action. 13(4). 126–129. 4 indexed citations
3.
Herrera, Rosa María Blanca, Marcus Low, Lindsay McKenna, et al.. (2023). Shorter TB treatment regimens should be safer as well. Public Health Action. 13(3). 104–106. 6 indexed citations
4.
Frick, Mike, Javier G. Castillo, Rosa María Blanca Herrera, et al.. (2023). One size does not fit all: community views on choices for TB treatment and prevention. Public Health Action. 13(3). 67–69. 2 indexed citations
5.
Denkinger, Claudia M., Jennifer Furin, Petra Heitkamp, et al.. (2023). Diagnostics to support the scaling up of shorter, safer tuberculosis regimens. The Lancet Microbe. 4(10). e758–e760. 3 indexed citations
6.
Rahman, Rifat, et al.. (2022). Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different. PLoS ONE. 17(7). e0271102–e0271102. 5 indexed citations
7.
Gotham, Dzintars, et al.. (2021). Public investments in the development of GeneXpert molecular diagnostic technology. PLoS ONE. 16(8). e0256883–e0256883. 18 indexed citations
8.
Perrin, Christophe, James A. Seddon, Jennifer Furin, et al.. (2020). Access to paediatric formulations for the treatment of childhood tuberculosis. The Lancet Child & Adolescent Health. 4(12). 855–857. 4 indexed citations
9.
Gotham, Dzintars, Lindsay McKenna, Mike Frick, & Erica Lessem. (2020). Public investments in the clinical development of bedaquiline. PLoS ONE. 15(9). e0239118–e0239118. 15 indexed citations
10.
Guglielmetti, Lorenzo, Marcus Low, & Lindsay McKenna. (2020). Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking. Expert Review of Anti-infective Therapy. 18(8). 701–704. 4 indexed citations
11.
Dooley, Kelly E., Peter J. Dodd, Anthony J. Garcia‐Prats, et al.. (2019). Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. The Lancet Child & Adolescent Health. 3(9). 636–645. 14 indexed citations
12.
Detjen, Anne, Lindsay McKenna, Stephen M. Graham, Ben J. Marais, & Farhana Amanullah. (2018). The upcoming UN general assembly resolution on tuberculosis must also benefit children. The Lancet Global Health. 6(5). e485–e486. 3 indexed citations
13.
Hoddinott, Graeme, Suzanne Staples, Rachel Brown, et al.. (2018). Community engagement for paediatric MDR-TB clinical trials: principles to support ethical trial implementation. The International Journal of Tuberculosis and Lung Disease. 22(5). 40–45. 3 indexed citations
14.
Harausz, Elizabeth, Anthony J. Garcia‐Prats, James A. Seddon, et al.. (2017). New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. American Journal of Respiratory and Critical Care Medicine. 195(10). 1300–1310. 54 indexed citations
15.
McKenna, Lindsay, et al.. (2017). A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials. Clinical Infectious Diseases. 65(8). 1383–1387. 15 indexed citations
16.
Schaaf, H. Simon, Anthony J. Garcia‐Prats, Lindsay McKenna, & James A. Seddon. (2017). Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Review of Clinical Pharmacology. 11(3). 233–244. 14 indexed citations
17.
Seddon, James A., et al.. (2015). Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children. Clinical Infectious Diseases. 61(suppl 3). S188–S199. 8 indexed citations
18.
Lessem, Erica, Helen Cox, Colleen Daniels, et al.. (2015). Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives. International Journal of Infectious Diseases. 32. 56–60. 27 indexed citations
19.
Clayden, Polly, Simon Collins, Colleen Daniels, et al.. (2014). 2014 PIPELINE REPORT HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS (TB) DRUGS, DIAGNOSTICS, VACCINES, PREVENTIVE TECHNOLOGIES, RESEARCH TOWARD A CURE, AND IMMUNE-BASED AND GENE THERAPIES IN DEVELOPMENT. 1 indexed citations
20.
Robertson, Valma J, et al.. (2001). Guidelines for the Clinical Use of Electrophysical Agents. Queensland's institutional digital repository (The University of Queensland). 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erica Lessem Breakdown of academic impact, for papers by Catherine Hewison Breakdown of academic impact, for papers by Nicole Salazar‐Austin Breakdown of academic impact, for papers by P. Gräf Breakdown of academic impact, for papers by Joseph Drabo Breakdown of academic impact, for papers by Julia Coit Breakdown of academic impact, for papers by Oswaldo Jave Breakdown of academic impact, for papers by Burcu Ceylan Cura Yayla Breakdown of academic impact, for papers by Charles M. Crane Breakdown of academic impact, for papers by Alexandra B. Souza
Rankless by CCL
2026